Figure 7.

In vivo anti-tumour activity of WTC-01 in a human NPC-TW01 xenograft model. (A) The pharmacokinetics of WTC-01, after i.p. injection. Mice (n = 4) were injected with 25 or 50 mg·kg⁻¹ of WTC-01 and blood samples were drawn at the indicated times. Serum was isolated and the amount of WTC-01 in the serum sample was measured. (B) Nude mice (n = 5) were subcutaneously injected with NPC-TW01 cells. After 7 days, the mice received i.p. injection of 25 or 50 mg·kg⁻¹ WTC-01 once every 3 days. Vincristine was used as a positive control at a dose of 10 mg·kg⁻¹ once a week. Tumour size was measured every three day Data shown are means ± SD. *P < 0.05 compared with control group; Student's t-test.